Translational Medicine Program, Division of General and Thoracic Surgery, The Hospital for Sick Children, Toronto, ON, Canada.
Cell Biology Program, Division of Gastroenterology, Hepatology and Nutrition, The Hospital for Sick Children, Toronto, ON, Canada.
Pediatr Res. 2022 Jan;91(1):101-106. doi: 10.1038/s41390-021-01657-6. Epub 2021 Sep 24.
Stem cell therapy has been proven to rescue intestinal injury and stimulate intestinal regeneration in necrotizing enterocolitis (NEC). Specifically, stem cells derived from amniotic fluid (AFSCs) and mesenchymal stem cells (MSCs) derived from bone marrow have shown promising results in the treatment of experimental NEC. This study aims to examine the effects of AFSCs and MSCs on the prevention of intestinal injury during experimental NEC.
Supernatants from AFSC and MSC cultures were collected to perform proteomic analysis. Prior to NEC induction, mice received intraperitoneal injections of phosphate-buffered saline (PBS), 2 × 10 AFSCs, or 2 × 10 MSCs.
We found that AFSCs grew faster than MSCs. Proteomic analysis indicated that AFSCs are primarily involved in cell development and growth, while MSCs are involved in immune regulation. Administering AFSCs before NEC induction decreased NEC severity and mucosal inflammation. Intestinal proliferation and endogenous stem cell activation were increased after AFSC administration. However, administering MSCs before NEC induction had no beneficial effects.
This study demonstrated that AFSCs and MSCs have different protein release profiles. AFSCs can potentially be used as a preventative strategy for neonates at risk of NEC, while MSCs cannot be used.
AFSCs and MSCs have distinct protein secretory profiles, and AFSCs are primarily involved in cell development and growth, while MSCs are involved in immune regulation. AFSCs are unique in transiently enhancing healthy intestinal epithelial cell growth, which offers protection against the development of experimental NEC. The prevention of NEC via the administration of AFSCs should be evaluated in infants at great risk of developing NEC or in infants with early signs of NEC.
干细胞疗法已被证明可挽救坏死性小肠结肠炎（NEC）中的肠损伤并刺激肠再生。具体来说，源自羊水（AFSCs）的干细胞和源自骨髓的间充质干细胞（MSCs）在治疗实验性 NEC 方面显示出了有前景的结果。本研究旨在研究 AFSCs 和 MSCs 对实验性 NEC 中肠损伤预防的作用。
收集 AFSC 和 MSC 培养物的上清液进行蛋白质组学分析。在诱导 NEC 之前，给小鼠腹腔内注射磷酸盐缓冲盐水（PBS）、2×10 AFSCs 或 2×10 MSCs。
我们发现 AFSCs 的生长速度快于 MSCs。蛋白质组学分析表明，AFSCs 主要参与细胞发育和生长，而 MSCs 则参与免疫调节。在 NEC 诱导前给予 AFSCs 可降低 NEC 严重程度和黏膜炎症。AFSC 给药后，肠增殖和内源性干细胞激活增加。但是，在 NEC 诱导前给予 MSCs 没有益处。
本研究表明，AFSCs 和 MSCs 具有不同的蛋白质释放谱。AFSCs 可能可作为有 NEC 风险的新生儿的预防策略，而 MSCs 则不能。
AFSCs 和 MSCs 具有不同的蛋白质分泌谱，AFSCs 主要参与细胞发育和生长，而 MSCs 则参与免疫调节。AFSCs 的独特之处在于可短暂增强健康肠上皮细胞的生长，从而提供针对实验性 NEC 发展的保护。通过给予 AFSCs 预防 NEC 应在有发生 NEC 高风险的婴儿或有早期 NEC 迹象的婴儿中进行评估。
